School of Nursing; Department of Oncology, University of Texas at Austin, Austin, TX, USA.
Department of Psychology, College of Liberal Arts, University of Texas at Austin, Austin, TX, USA.
Biol Res Nurs. 2020 Jan;22(1):126-138. doi: 10.1177/1099800419887230. Epub 2019 Nov 10.
Accelerated brain aging has been proposed to explain cancer-related cognitive impairment, but empirical evidence for this relationship is lacking. The purpose of this study was to evaluate amyloid beta (Aβ) and tau, biomarkers of neurodegeneration, in relation to cognition in breast cancer survivors (BCSs). We explored relationships among peripheral concentrations of Aβ42, Aβ-40, tau, and cytokines; cognitive function; and psychosomatic symptoms in a cohort of BCSs post-chemotherapy.
This secondary analysis of a cross-sectional study was conducted with 65 BCSs. Serum total Aβ-42, Aβ-40, and tau levels were measured with single molecule array technology. Cytokines (interleukin [IL]-6, tumor necrosis factor [TNF]-α, granulocyte-macrophage colony-stimulating factor [GM-CSF], interferon [IFN]-g, IL-10, IL-12, IL-13, IL1-b, IL-2, IL-4, IL-5, IL-7, and IL-8) were simultaneously measured in serum using multiplex assays. Cognitive function was measured with five standardized neuropsychological tests and psychosomatic symptoms (stress, loneliness, anxiety, depressive symptoms, fatigue, sleep quality, and daytime sleepiness) with self-report questionnaires. Data analyses included correlations and random forest regression (RFR).
Significant correlations were identified among hip-to-waste ratio, number of treatment modalities, Aβ-42, Aβ-40, and tau levels (s = .27-.35, s < .05). RFR modeling including Aβ-42, Aβ-40, tau, and cytokines as features explained significant variance in cognitive function ( = .71, = 9.01, < .0001) and psychosomatic symptoms ( = .74, = 10.22, < .0001).
This study suggests that neurodegenerative biomarkers interact with cytokines to influence cognitive functioning and psychosomatic symptoms in BCSs following chemotherapy, but additional research is needed.
有人提出加速大脑衰老可以解释癌症相关的认知障碍，但这一关系的实证证据尚缺乏。本研究旨在评估β淀粉样蛋白（Aβ）和tau，这两种神经退行性变的生物标志物，与乳腺癌幸存者（BCS）认知功能的关系。我们在接受化疗后的乳腺癌幸存者队列中，探索了外周血 Aβ42、Aβ-40、tau 与细胞因子之间；认知功能之间；以及身心症状之间的关系。
本研究为一项横断面研究的二次分析，共纳入 65 名 BCS。采用单分子阵列技术检测血清总 Aβ-42、Aβ-40 和 tau 水平。采用多聚酶链式反应检测血清细胞因子（白细胞介素[IL]-6、肿瘤坏死因子[TNF]-α、粒细胞-巨噬细胞集落刺激因子[GM-CSF]、干扰素[IFN]-g、IL-10、IL-12、IL-13、IL1-b、IL-2、IL-4、IL-5、IL-7 和 IL-8）。使用标准化神经心理学测试评估认知功能，使用自我报告问卷评估身心症状（压力、孤独感、焦虑、抑郁症状、疲劳、睡眠质量和白天嗜睡）。数据分析包括相关性分析和随机森林回归（RFR）。
发现臀围与腰围比、治疗方式数量、Aβ-42、Aβ-40 和 tau 水平之间存在显著相关性（s =.27-.35，s <.05）。包含 Aβ-42、Aβ-40、tau 和细胞因子作为特征的 RFR 模型，可解释认知功能（ =.71， = 9.01， <.0001）和身心症状（ =.74， = 10.22， <.0001）的显著方差。
本研究表明，神经退行性生物标志物与细胞因子相互作用，影响化疗后乳腺癌幸存者的认知功能和身心症状，但还需要进一步研究。
